Applications of antiviral drugs in 456 patients with COVID-19

doi:10.19803/j.1672-8629.2022.04.15

Abstract

Abstract: Objective To evaluate the clinical characteristics of COVID-19 patients and current usage of antiviral drugs in our hospital to provide data for rational use drugs in cliuic. Methods The clinical data on COVID-19 patients diagnosed in Xiantao First People's Hospital from February 1 to February 29, 2020, their characteristics, as well as the usage, dosage and combined use of antiviral drugs and adverse drug reactions (ADR) were analyzed retrospectively. Results A total of 456 patients were collected. Patients aged 30 to 65 accounted for 71.71%. The usage and dosage of antiviral drugs basically conformed to the national diagnosis and treatment plans. Monotherapy was the main treatment, combined use of antiviral drugs accounted for 8.78%, and arbidol was the most frequently used. ADR occurred in 29 patients, and the main symptoms were nausea, vomiting and poor appetite. Conclusion The use of antiviral drugs in patients with COVID-19 was generally appropriate, but a few patients were treated with three or more types of antiviral drugs.

Key words: coronavirus disease 2019 (COVID-19), antiviral drug, retrospective study, adverse drug reaction

CLC Number:

R978.7

YANG Fan, MA Haiping, YOU Mengru, LIAO Sha, LIU Lan, ZHU Jun. Applications of antiviral drugs in 456 patients with COVID-19[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 413-416.

References

[1] Special Expert Group of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on the epidemiological characteristics of novel coronavirus pneumonia(COVID-19)[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2020, 41(2): 139-144.
[2] Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2020, 41(2): 145-151.
[3] General Office of the National Health Commission.Notice on the issuance of the COVID-19 protocol (Trial Seventh Edition)[EB/OL].(2020-03-05)[2020-05-05].http://www.gov.cn/zhengce/zhengceku/2020-03/04 content_5486705.htm.
[4] LU H.Drug treatment options for the 2019-new coronavirus(2019-nCoV)[J]. Biosci Trends,2020, 14: 69-71.
[5] Shanghai Clinical Treatment Expert Group for Corona Virus Disease 2019. Comprehensive treatment and management of corona virus disease 2019: expert consensus statement from Shanghai Disease 2019. Comprehensive treatment and management of corona virus disease 2019: expert consensus statement from Shanghai[J].Chinese Journal of Infectious Diseases(中华传染病杂志), 2020, 38(3): 134-138.
[6] DXY Medical Forum. Dialogue with Hu Bijie: Hydroxyl chloroquine has a good effect, and the use of hormones should be restrained [EB/OL].(2020-02-23)[2020-05-05].http://infect.dxy.cn/article/679735.
[7] LI Y, ZHAO L.Research status on pharmacological actions and in vitro and in vivo effects of arbidol against respiratory viruses[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学杂志), 2019, 35(17): 1964-1968.
[8] BROOKS MJ, BURTSEVA EI, ELLERY PJ, et al.Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions[J]. Med Virol, 2012, 84(1): 170-181.
[9] WANG MZ, CAI BQ, LI LY, et al.Efficacy and safety of arbidol in treatment of naturally acquired influenza[J].Acta Academiae Medicinae Sinicae(中国医学科学院学报), 2004, 26(3): 289-293.
[10] SHI L, XIONG H, HE J, et al.Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus, and adenovirus in vitro and in vivo[J].Arch Virol, 2007, 152(8): 1447-55.
[11] BORISKIN Y, LENEVA I, PECHEUR EI, et al.Arbidol: a broad-spectrum antiviral compound that blocks viral fusion[J]. Curr Med Chem, 2008, 15(10): 997-1005.
[12] YE LH, XU YS, DENG Y, et al.Research progress on potential drug interactions of anticoronavirus disease 2019 drugs[J]. Drugs & Clinic(现代药物与临床), 2020, 35(4): 607-613.
[13] JI XG, ZHAO YH, ZHANG M, et al.The experimental study of the anti-SARS-CoV effect of arbidole[J]. Pharmaceutical Journal of Chinese People’s Liberation Army(解放军药学学报),2004, 20(4): 274-276.
[14] KHAMITOY RA, LOGINOVA SY, SHCHUKINA VN, et al.Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures[J].Vopr Virusol, 2008, 53(4): 9-13.
[15] GUAN WD, DU QL, JIANG HM, et al.Comparison of inhibitory effects of arbidol and Lianhuaqingwen capsules on Middle East respiratory syndrome coronavirus in vitro and in vivo[J]. Guangdong Medical Journal(广东医学), 2018, 39(23): 3454-3458.
[16] Changjiang Daily. Academician LI Lanjuan's team released significant antiviral research results[EB/OL].(2020-03-06) [2020-05-05]. http://www.thecover.cn/news/3508828.
[17] Xinmin Evening News. Shanghai's guidelines for diagnosis and treatment could be released as soon as this week[EB/OL].(2020-03-04)[2020-05-05]. http://paper.xinmin.cn/html/xmwb/2020-02-17/3/57838.html.
[18] WEI HT, SHEN S, DI X, et al.Literature analysis of common adverse drug reactions due to short-term use of chloroquine/hydroxychloroquine and recommendations[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(4): 202-207.
[19] CAI J, LI HX, LIU MY, et al.Safe use of lopinavir/ritonavir for COVID-19 based on literature analysis of adverse reactions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(6): 326-331.
[20] WANG T, SONG HB, TIAN CH.Risks posed by anti-novel coronavirus pneumonia drug-arbidol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(4): 198-201.
[21] SI X, SONG RJ, FENG YF, et al.Efficacy and safety of arbidol hydrochloride for respiratory viral infection in Chinese population:a systematic review[J]. Clinical Medication Journal(临床药物治疗杂志), 2020, 18(3): 31-37.
[22] PANG WY, WANG QY, ZHAO ZG.Application and evaluation of arbidol in treating viral diseases[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(6): 321-325.